Combined Therapy of Intravitreal Bevacizumab and Posterior Subtenon Triamcinolone Injection in Macular Edema with Branch Retinal Vein Occlusion.

Cho, Aran; Choi, Kyung Seek; Rhee, Mi Ri; Lee, Sung Jin

doi:2012.53.2.276

J Korean Ophthalmol Soc > Volume 53(2); 2012 > Article

Original Article

Journal of the Korean Ophthalmological Society 2012;53(2):276-282.
DOI: https://doi.org/10.3341/jkos.2012.53.2.276 Published online February 15, 2012.

Combined Therapy of Intravitreal Bevacizumab and Posterior Subtenon Triamcinolone Injection in Macular Edema with Branch Retinal Vein Occlusion.

Aran Cho, Kyung Seek Choi, Mi Ri Rhee, Sung Jin Lee

¹Department of Ophthalmology, Soonchunhyang University College of Medicine, Seoul, Korea. wismile@unitel.co.kr
²Myeong Eye Clinic, Seoul, Korea.

망막분지정맥폐쇄에 동반된 황반부종의 유리체내 베바시주맙 및 후테논낭하 트리암시놀론 병합요법

조아란¹⋅최경식¹⋅이미리²⋅이성진¹

Department of Ophthalmology, Soonchunhyang University College of Medicine¹, Seoul, Korea Myeong Eye Clinic², Seoul, Korea

Abstract

PURPOSE
To compare the clinical outcomes of intravitreal bevacizumab with and without posterior subtenon triamcinolone acetonide injections for macular edema with branch retinal vein occlusion. METHODS: Intravitreal bevacizumab injection (single group) or intravitreal bevacizumab injection with posterior subtenon triamcinolone acetonide injection (combined group) were performed in 30 eyes each, and intravitreal bevacizumab injection was given once a month in both groups until macular edema was in the normal range. A best corrected visual acuity and central macular thickness were measured pre- and post-injection. RESULTS: The required number of injections to achieve improved macular edema in the normal range was 2.8 +/- 0.5 times in the single group and 2.0 +/- 0.6 times in the combined group. Six months after injection, average central macular thickness decreased to 185.3 +/- 63.5 microm in the single group and to 260.0 +/- 74.6 microm in the combined group. The best corrected visual acuity (log MAR) improved from 0.71 +/- 0.63 to 0.35 +/- 0.44 in the single group and from 0.67 +/- 0.42 to 0.08 +/- 0.11 in the combined group. The number of cases in which the central macular thickness increased again within 6 months after the injections was 19 eyes in the single group and 6 eyes in the combined group. CONCLUSIONS: In macular edema with branch retinal vein occlusion, early rapid recovery of visual acuity and decrease of central macular thickness were observed due to the synergistic effect of bevacizumab and triamcinolone acetonide in combined therapy, and the recurrence frequency of macular edema was reduced by the long-term effect instilled by the long half-life of triamcinolone acetonide.

Key Words: Bevacizumab;Branch retinal occlusion;Combined therapy;Macular edema;Triamcinolone